-
1دورية أكاديمية
المؤلفون: Pike, KG, Hunt, TA, Barlaam, B, Benstead, D, Cadogan, E, Chen, K, Cook, CR, Colclough, N, Deng, C, Durant, ST, Eatherton, A, Goldberg, K, Johnstrom, P, Liu, LB, Liu, ZQ, Nissink, JWM, Pang, CL, Pass, M, Robb, GR, Roberts, C, Schou, M, Steward, O, Sykes, A, Yan, YM, Zhai, BC, Zheng, L
المصدر: Journal of medicinal chemistry. 67(4):3090-3111
مصطلحات موضوعية: Medicin och hälsovetenskap
-
2دورية أكاديمية
المؤلفون: Kettle, JG, Bagal, SK, Barratt, D, Bodnarchuk, MS, Boyd, S, Braybrooke, E, Breed, J, Cassar, DJ, Cosulich, S, Davies, M, Davies, NL, Deng, C, Eatherton, A, Evans, L, Feron, LJ, Fillery, S, Gleave, ES, Goldberg, FW, Gonzalez, MAC, Guerot, C, Haider, A, Harlfinger, S, Howells, R, Jackson, A, Johnstrom, P, Kemmitt, PD, Koers, A, Kondrashov, M, Lamont, GM, Lamont, S, Lewis, HJ, Liu, LB, Mylrea, M, Nash, S, Niedbala, MJ, Peter, A, Phillips, C, Pike, K, Raubo, P, Robb, GR, Ross, S, Sanders, MG, Schou, M, Simpson, I, Steward, O
المصدر: Journal of medicinal chemistry. 66(13):9147-9160
مصطلحات موضوعية: Medicin och hälsovetenskap
-
3دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
4دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
5دورية أكاديمية
المصدر: BMC Biotechnology, Vol 11, Iss 1, p 72 (2011)
مصطلحات موضوعية: Biotechnology, TP248.13-248.65
وصف الملف: electronic resource
-
6دورية أكاديمية
المؤلفون: Quinn TR; Early TDE Discovery, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Giblin KA; Early TDE Discovery, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Thomson C; Early TDE Discovery, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Boerth JA; Early TDE Discovery, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Bommakanti G; Early TDE Discovery, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Braybrooke E; Early TDE Discovery, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Chan C; Early TDE Discovery, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Chinn AJ; Early TDE Discovery, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Code E; Discovery Sciences, R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Cui C; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China., Fan Y; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China., Grimster NP; Early TDE Discovery, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Kohara K; Early TDE Discovery, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Lamb ML; Early TDE Discovery, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Ma L; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China., Mfuh AM; Early TDE Discovery, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Robb GR; Early TDE Discovery, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Robbins KJ; Early TDE Discovery, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Schimpl M; Discovery Sciences, R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Tang H; Discovery Sciences, R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Ware J; Discovery Sciences, R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Wrigley GL; Early TDE Discovery, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Xue L; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China., Zhang Y; Early TDE Discovery, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Zhu H; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China., Hughes SJ; Early TDE Discovery, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.
المصدر: Journal of medicinal chemistry [J Med Chem] 2024 Aug 22; Vol. 67 (16), pp. 14210-14233. Date of Electronic Publication: 2024 Aug 12.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
مواضيع طبية MeSH: Proto-Oncogene Proteins c-cbl*/antagonists & inhibitors , Proto-Oncogene Proteins c-cbl*/metabolism , Proto-Oncogene Mas* , Drug Design* , Carbamates*/chemistry , Carbamates*/pharmacology , Carbamates*/chemical synthesis, Humans ; Structure-Activity Relationship ; Models, Molecular ; Artificial Intelligence ; Drug Discovery ; Adaptor Proteins, Signal Transducing
-
7دورية أكاديمية
المؤلفون: Smith JM; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Barlaam B; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Beattie D; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Bradshaw L; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Chan HM; Research and Early Development, Oncology R&D, AstraZeneca, Waltham 02451, United States., Chiarparin E; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Collingwood O; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Cooke SL; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Cronin A; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Cumming I; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Dean E; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Debreczeni JÉ; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Del Barco Barrantes I; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Diene C; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Gianni D; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Guerot C; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Guo X; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Guven S; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Hayhow TG; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Hong T; Research and Early Development, Oncology R&D, AstraZeneca, Waltham 02451, United States., Kemmitt PD; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Lamont GM; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Lamont S; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Lynch JT; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., McWilliams L; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Moore S; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Raubo P; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Robb GR; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Robinson J; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Scott JS; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Srinivasan B; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Steward O; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Stubbs CJ; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Syson K; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Tan L; Pharmaron Beijing Company, Ltd., Beijing 100176, P. R. China., Turner O; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Underwood E; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Urosevic J; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Vazquez-Chantada M; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Whittaker AL; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Wilson DM; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom., Winter-Holt JJ; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
المصدر: Journal of medicinal chemistry [J Med Chem] 2024 Aug 22; Vol. 67 (16), pp. 13604-13638. Date of Electronic Publication: 2024 Jul 30.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
مواضيع طبية MeSH: Protein-Arginine N-Methyltransferases*/antagonists & inhibitors , Protein-Arginine N-Methyltransferases*/metabolism , Enzyme Inhibitors*/pharmacology , Enzyme Inhibitors*/chemistry , Enzyme Inhibitors*/chemical synthesis, Humans ; Animals ; Structure-Activity Relationship ; Mice ; Drug Discovery ; Cell Line, Tumor ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/chemical synthesis
-
8دورية أكاديمية
المؤلفون: Atkinson SJ; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Bagal SK; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Argyrou A; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Askin S; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Cheung T; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Chiarparin E; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Coen M; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Collie IT; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Dale IL; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., De Fusco C; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Dillman K; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Evans L; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Feron LJ; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Foster AJ; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Grondine M; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Kantae V; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Lamont GM; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Lamont S; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Lynch JT; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Nilsson Lill S; Data Sciences & Modelling, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 431 83, Sweden., Robb GR; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Saeh J; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Schimpl M; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Scott JS; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Smith J; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Srinivasan B; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Tentarelli S; Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Vazquez-Chantada M; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Wagner D; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Walsh JJ; Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Watson D; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Williamson B; Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.
المصدر: Journal of medicinal chemistry [J Med Chem] 2024 Mar 28; Vol. 67 (6), pp. 4541-4559. Date of Electronic Publication: 2024 Mar 11.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
مواضيع طبية MeSH: Neoplasms*, Humans ; Entropy ; Methionine Adenosyltransferase/metabolism
-
9دورية أكاديمية
المؤلفون: Mojica N; Department of Chemistry, University of Oslo, NO-0315 Blindern, Oslo, Norway., Kersten F; Department of Chemistry, University of Oslo, NO-0315 Blindern, Oslo, Norway.; Centre for Molecular Medicine Norway, University of Oslo, NO-0318 Blindern, Oslo, Norway., Montserrat-Canals M; Department of Chemistry, University of Oslo, NO-0315 Blindern, Oslo, Norway.; Centre for Molecular Medicine Norway, University of Oslo, NO-0318 Blindern, Oslo, Norway., Huhn Iii GR; Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32816, United States., Tislevoll AM; Department of Chemistry, University of Oslo, NO-0315 Blindern, Oslo, Norway., Cordara G; Department of Chemistry, University of Oslo, NO-0315 Blindern, Oslo, Norway., Teter K; Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida 32816, United States., Krengel U; Department of Chemistry, University of Oslo, NO-0315 Blindern, Oslo, Norway.
المصدر: Biochemistry [Biochemistry] 2024 Mar 05; Vol. 63 (5), pp. 587-598. Date of Electronic Publication: 2024 Feb 15.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 0370623 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4995 (Electronic) Linking ISSN: 00062960 NLM ISO Abbreviation: Biochemistry Subsets: MEDLINE
مواضيع طبية MeSH: Escherichia coli*/genetics , Escherichia coli*/metabolism , Vibrio*, Enterotoxins/metabolism ; Cholera Toxin/metabolism
SCR Organism: Vibrio natriegens
-
10دورية أكاديمية
المؤلفون: Mfuh AM; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Boerth JA; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Bommakanti G; Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Chan C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Chinn AJ; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Code E; Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Fricke PJ; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Giblin KA; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Gohlke A; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Hansel C; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Hariparsad N; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Hughes SJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Jin M; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Kantae V; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Kavanagh SL; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Lamb ML; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Lane J; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Moore R; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Puri T; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Quinn TR; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Reddy I; Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Robb GR; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Robbins KJ; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Gancedo Rodrigo M; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K.; Isomorphic Laboratories, 280 Bishopsgate, London EC2M 4RB, U.K., Schimpl M; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Singh B; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Singh M; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Tang H; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Thomson C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Walsh JJ; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Ware J; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Watson IDG; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Ye MW; Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Wrigley GL; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Zhang AX; Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Zhang Y; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Grimster NP; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.
المصدر: Journal of medicinal chemistry [J Med Chem] 2024 Jan 25; Vol. 67 (2), pp. 1500-1512. Date of Electronic Publication: 2024 Jan 16.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE